FR0012127173 - Common Stock

**OSE** gets a fundamental rating of **2** out of 10. The analysis compared the fundamentals against 80 industry peers in the **Biotechnology** industry. **OSE** may be in some trouble as it scores bad on both profitability and health. **OSE** has a decent growth rate and is not valued too expensively.

In the past year **OSE** has reported negative net income.

In the past year **OSE** has reported a negative cash flow from operations.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -28.03% | ||

ROE | -100.12% | ||

ROIC | N/A |

ROA(3y)-21.31%

ROA(5y)-17.25%

ROE(3y)-63.23%

ROE(5y)-44.92%

ROIC(3y)N/A

ROIC(5y)N/A

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

The number of shares outstanding for **OSE** has been increased compared to 5 years ago.

Based on the Altman-Z score of **-0.30**, we must say that **OSE** is in the distress zone and has some risk of bankruptcy.

The **Altman-Z score** of **OSE** (**-0.30**) is comparable to the rest of the industry.

Looking at the **Debt to Equity ratio**, with a value of **1.68**, **OSE** is doing worse than **65.33%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.68 | ||

Debt/FCF | N/A | ||

Altman-Z | -0.3 |

ROIC/WACCN/A

WACC7.69%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.62 | ||

Quick Ratio | 1.62 |

Looking at the last year, **OSE** shows a very negative growth in **Revenue**. The Revenue has decreased by **-87.83%** in the last year.

The Revenue for **OSE** have been decreasing by **-38.07%** on average. This is quite bad

EPS 1Y (TTM)-22.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%36.18%

Revenue 1Y (TTM)-87.83%

Revenue growth 3Y-40.23%

Revenue growth 5Y-38.07%

Sales Q2Q%-61.46%

The **Earnings Per Share** is expected to grow by **75.64%** on average over the next years. This is a very strong growth

EPS Next Y174.79%

EPS Next 2Y106.51%

EPS Next 3Y75.64%

EPS Next 5YN/A

Revenue Next Year197.62%

Revenue Next 2Y101%

Revenue Next 3Y76.27%

Revenue Next 5YN/A

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The **Price/Earnings Ratio** is negative for **OSE**. In the last year negative earnings were reported.

Based on the **Price/Forward Earnings** ratio, **OSE** is valued cheaper than 92.00% of the companies in the same industry.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **20.69**, **OSE** is valued rather cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 7.3 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y106.51%

EPS Next 3Y75.64%

No dividends for **OSE**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**OSE IMMUNO**

EPA:OSE (7/24/2024, 2:41:01 PM)

**6.65**

**+0.21 (+3.26%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap144.66M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 7.3 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -28.03% | ||

ROE | -100.12% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.68 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.62 | ||

Quick Ratio | 1.62 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-22.67%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y174.79%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-87.83%

Revenue growth 3Y-40.23%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y